Skip to main content
. 2020 Sep 15;11(9):760. doi: 10.1038/s41419-020-02980-2

Fig. 1. TNBC expressed a high level of c-myc and is insensitive to Palbociclib than non-TNBC.

Fig. 1

a Half-maximal inhibitory concentration (IC50) of palbociclib for 11 human breast cancer cell lines were calculated based on the results of CCK-8 assay. b Left shows volcano plot comparing the P value versus fold change for genes from TNBC relative to non-TNBC patients. The vertical lines correspond to 2.0-fold up and down, and the horizontal line represents a P value of 0.001. Genes labeled in red represent the significantly expressed genes. Right illustrates the top 10 highly expressed genes in TNBC compared to non-TNBC patients. c Western blot analysis of lysates from 11 human breast cancer cell lines. d Up: representative immunohistochemical staining of c-myc low, medium, or high expression. Down: expression of c-myc by immunohistochemical staining in 124 breast cancer samples in tissue microarrays. e C-myc mRNA expression in luminal (n = 566), HER2 positive (n = 37), and triple-negative (n = 116) breast cancer samples from The Cancer Genome Atlas (TCGA) database. f IC50 values for MCF-7 cell transfected with c-myc plasmid and MDA-MB-231 cell transfected with c-myc shRNA treated with palbociclib for 48 h. Representative images and data based on three independent experiments. Error bars indicate mean ± standard deviation.